FFM
RPRX icon

Fullerton Fund Management’s Royalty Pharma RPRX Stock Holding History

Fullerton Fund Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-17,073
Closed -$602K – 152
2025
Q3 		$602K Buy
17,073
+5,579
+49% +$202K 0.02% 76
2025
Q2 		$414K Buy
+11,494
New +$381K 0.02% 78
2025
Q1 		– Sell
-15,205
Closed -$388K – 144
2024
Q4 		$388K Hold
15,205
– – 0.01% 85
2024
Q3 		$430K Sell
15,205
-797
-5% -$22.1K 0.02% 86
2024
Q2 		$422K Buy
+16,002
New +$444K 0.02% 102

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fullerton Fund Management's RPRX Position: Q4 2025 in Review

Fullerton Fund Management sold out of Royalty Pharma (RPRX) in Q4 2025, closing a stake of 17,073 shares — an estimated $602K sold.

Fullerton Fund Management first reported a position in RPRX in Q2 2024 and held it in 5 quarters. The position peaked at $602K in Q3 2025. 540 funds tracked by Wall St. Rank hold RPRX as of Q4 2025.

  • Fullerton Fund Management reported no remaining Royalty Pharma position as of Q4 2025 after selling out during the quarter.
  • Fullerton Fund Management sold 17,073 Royalty Pharma shares in Q4 2025, an estimated $602K.
  • Fullerton Fund Management first reported a position in Royalty Pharma in Q2 2024 and held it in 5 quarters.
  • Fullerton Fund Management's Royalty Pharma position peaked at $602K in Q3 2025.
  • 540 funds tracked by Wall St. Rank held Royalty Pharma as of Q4 2025.

Based on Fullerton Fund Management's 13F filing for Q4 2025, filed 17 Feb 2026.